Hepatic Function at High Altitudes

Siegfried, Berendsohn S.

doi:10.1001/archinte.1962.03620150006002

Cited by 14 publications

(2 citation statements)

References 31 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This condition not only affects the hematopoietic system but also has implications for other organs. The liver, serving as a central hub for numerous metabolic processes and having a high oxygen demand, is susceptible to structural and functional changes under hypoxic conditions ( 30 ). Also, hypoxia-induced inflammation and disruptions in other organs may exert an influence on liver function ( 30 , 31 ).…”

Section: Discussionmentioning

confidence: 99%

“…The liver, serving as a central hub for numerous metabolic processes and having a high oxygen demand, is susceptible to structural and functional changes under hypoxic conditions ( 30 ). Also, hypoxia-induced inflammation and disruptions in other organs may exert an influence on liver function ( 30 , 31 ). Previous studies have suggested that hypoxia affects the lipid metabolism of the liver ( 32 ).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Metabolomics reveals altered metabolites in cirrhotic patients with severe portal hypertension in Tibetan population

Ye,

Xia,

et al. 2024

Front. Med.

View full text Add to dashboard Cite

BackgroundPortal hypertension (PHT) presents a challenging issue of liver cirrhosis. This study aims to identify novel biomarkers for severe PHT (SPHT) and explore the pathophysiological mechanisms underlying PHT progression.MethodsTwenty-three Tibetan cirrhotic patients who underwent hepatic venous pressure gradient (HVPG) measurement were included. Eleven patients had an HVPG between 5 mmHg and 15 mmHg (MPHT), while 12 had an HVPG ≥16 mmHg (SPHT). Peripheral sera were analyzed using liquid chromatograph-mass spectrometer for metabolomic assessment. An additional 14 patients were recruited for validation of metabolites.ResultsSeven hundred forty-five metabolites were detected and significant differences in metabolomics between MPHT and SPHT patients were observed. Employing a threshold of p < 0.05 and a variable importance in projection score >1, 153 differential metabolites were identified. A significant number of these metabolites were lipids and lipid-like molecules. Pisumionoside and N-decanoylglycine (N-DG) exhibited the highest area under the curve (AUC) values (0.947 and 0.9091, respectively). Additional differential metabolites with AUC >0.8 included 6-(4-ethyl-2-methoxyphenoxy)-3,4,5-trihydroxyoxane-2-carboxylic acid, sphinganine 1-phosphate, 4-hydroxytriazolam, 4,5-dihydroorotic acid, 6-hydroxy-1H-indole-3-acetamide, 7alpha-(thiomethyl)spironolactone, 6-deoxohomodolichosterone, glutaminylisoleucine, taurocholic acid 3-sulfate, and Phe Ser. Enzyme-linked immunosorbent assay further confirmed elevated levels of sphinganine 1-phosphate, N-DG, and serotonin in SPHT patients. Significant disruptions in linoleic acid, amino acid, sphingolipid metabolisms, and the citrate cycle were observed in SPHT patients.ConclusionPisumionoside and N-DG are identified as promising biomarkers for SPHT. The progression of PHT may be associated with disturbances in lipid, linoleic acid, and amino acid metabolisms, as well as alterations in the citrate cycle.

show abstract

Section: Discussionmentioning

confidence: 99%